Psyence Biomedical stock soars after partner achieves ibogaine breakthrough

Published 31/07/2025, 12:58
© Reuters.

Investing.com -- Psyence Biomedical Ltd. (NASDAQ:PBM) stock surged 70% after the company announced that its strategic partner, PsyLabs, successfully produced a GMP-aligned Ibogaine Total (EPA:TTEF) Alkaloid extract.

The high-purity extract met all microbial safety standards for food-grade consumption, as verified by an accredited third-party laboratory. This breakthrough represents a significant milestone in the production of purified psychedelic compounds, potentially advancing the company’s pharmaceutical development efforts.

Psyence BioMed acquired an equity stake in PsyLabs in 2024 and continued that investment in 2025. The collaboration has supported PsyLabs’ development of scalable, compliant psychedelic active pharmaceutical ingredients (APIs).

"This is a groundbreaking moment for our entire team on the ground who have put countless hours and effort into ensuring our naturally derived, sustainable input materials are extracted with the same caution, mindfulness, and care, all covering the GMP manufacturing processes," said Cody Robyn Futeran, Head of Extraction Innovations and Business Development at PsyLabs.

PsyLabs is currently expanding its chemistry production area to meet growing demand for Ibogaine HCL, Psilocybin Isolate, and other 90% purity SKUs derived from both Iboga and Mushrooms. The company plans to make its Ibogaine available to licensed research institutions and developers worldwide.

Tony Budden, CEO of PsyLabs, noted that the team is "committed to refining our processes to achieve even higher purity levels, supporting the growing demand for high-quality psychedelic APIs."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.